The European Commission has granted Orphan Drug Designation to RedHill Biopharma’s (NASDAQ: RDHL) lead asset RHB-204 for the treatment of nontuberculous mycobacteria (NTM) disease.
Cameron Smith has been dominating golf headlines throughout the last few months. From a blistering putting display at St. Andrews to win the Open Championship, to rumors that the Australian upstart is leaving for the LIV Golf Tour, Smith has been getting a lot of airtime.
I-Mab (NASDAQ:IMAB) disclosed in an SEC filing that AbbVie Inc (NYSE:ABBV) would discontinue the global Phase 1b study of lemzoparlimab combination therapy with…
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) and its subsidiary Intercept Pharma Europe Limited settled patent litigation with Dr. Reddy’s Laboratories Ltd (NYSE:RDY). The litigation concerns…
Palisade Bio (NASDAQ: PALI) has dosed first patient in its Phase 3 study evaluating lead asset LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.